Topic
Drug Pipeline
Myostatin and activin-pathway drugs — apitegromab, bimagrumab, taldefgrobep, garetosmab, sotatercept, ACE-031 — with the real trial data.
10 articles
Trevogrumab: The Regeneron Myostatin Blocker Behind COURAGE
Trevogrumab is Regeneron's anti-myostatin antibody. In the COURAGE trial it cut the muscle loss people normally suffer on semaglutide roughly in half, and a three-drug version preserved 81 percent of lean mass. Here is the data, the safety trade-off, and why you cannot buy it.
Sotatercept and the Activin Pathway: Beyond Myostatin
Sotatercept (Winrevair) is an ActRIIA-Fc fusion that started as a muscle drug, became the first activin-signaling inhibitor approved for pulmonary arterial hypertension, and proves that traps in this pathway can save lives outside the muscle field.
Garetosmab and FOP: Regeneron's Activin A Blocker Explained
Garetosmab is Regeneron's activin A antibody for fibrodysplasia ossificans progressiva. Inside the OPTIMA Phase 3 trial, the 94% reduction in new bone lesions, the FDA priority review, and how it ties back to myostatin pathway biology.
Taldefgrobep Alfa: Biohaven's Bet on Muscle-Preserving Weight Loss
Taldefgrobep alfa missed its SMA primary endpoint, but its body-composition data was strong enough to relaunch Biohaven as a contender in the muscle-sparing obesity race. Here is the full status as of May 2026.
ACE-031 (Ramatercept): Why the Original Myostatin Drug Failed
ACE-031 was the first ActRIIB-Fc trap to reach DMD trials. Inside the real Acceleron history, the epistaxis and telangiectasia that ended Phase 2, the ramatercept rename, and why peptide vendors selling 'ACE-031' are not selling the same molecule.
Apitegromab: Scholar Rock's Myostatin Drug for SMA
Apitegromab is the first myostatin-targeted therapy to hit a Phase 3 endpoint in SMA. Here is what SAPPHIRE actually showed, how the drug is dosed, and where FDA review stands in 2026.
Bimagrumab: The Activin Receptor Antibody Lilly Paired With Semaglutide
Bimagrumab is the ActRII antibody Lilly bought for 1.9 billion dollars. Here is the BELIEVE trial data, the JAMA T2DM results, the muscle-spasm problem, and why Lilly hit pause.
Anti-Myostatin Antibodies and Drug Candidates: MYO-029, BMS-986089, LY2495655
Anti-myostatin antibodies include research reagents and clinical drug candidates. This guide explains MYO-029, domagrozumab, BMS-986089, LY2495655, trevogrumab, apitegromab, and what failed trials taught.
Best Myostatin Inhibitor: Ranking Options by Evidence, Not Hype
The best myostatin inhibitor depends on the goal. This evidence-led ranking separates training, creatine, epicatechin, drugs, peptides, and supplement marketing.
Myostatin Inhibitor Drugs: Current Pipeline and Failed Candidates
Myostatin inhibitor drugs are moving through SMA, obesity, and lean-mass trials. This evidence-first update explains apitegromab, bimagrumab, trevogrumab, taldefgrobep alfa, and older failed candidates.